WASHINGTON (AP) — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations ...

The drugs identified for negotiation in the second round include: Ozempic, Wegovy and other GPL-inhibitors are in high demand in the U.S. Due to that demand, Medicare covering them for diabetes ...

Everyone is talking about or using weight loss products. So, the government pounces. A batch of 17 drugs are on a list of ...

Sales to Medicare, the US health program for seniors ... “Today’s announcement means Americans may finally get a better deal on Ozempic and Wegovy — but only if Trump does not walk away ...

Feb 21 (Reuters) - The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

Health-care professionals, eager to support their patients diagnosed with diabetes or obesity, are writing more prescriptions ...

The FDA has declared that the shortage of popular weight-loss drugs, including Ozempic and Wegovy, is officially over.

WASHINGTON — Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare's list of medications that will be negotiated directly between the government and drug manufacturers ...

Weight loss drugs Ozempic and Wegovy have been added to the list of medications Medicare will be able to negotiate directly with drug manufacturers, potentially leading to savings for consumers.